THYMIC CARCINOMA
Clinical trials for THYMIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new THYMIC CARCINOMA trials appear
Sign up with your email to follow new studies for THYMIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy offers hope for rare thymus cancers after standard treatment fails
Disease control Recruiting nowThis study tests a combination of two drugs, tislelizumab and anlotinib, as a second treatment option for people with thymoma or thymic carcinoma whose cancer worsened after initial chemotherapy. The trial will enroll 20 participants and measure how many patients see their tumors…
Matched conditions: THYMIC CARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 26, 2026 04:02 UTC
-
Engineered immune cells take on rare thymus cancers
Disease control Recruiting nowThis early-stage study tests a new treatment using specially engineered immune cells (CAR-NK cells) to attack cancer cells in adults with thymoma or thymic carcinoma that has come back or not responded to standard therapy. About 36 participants will receive one of three types of …
Matched conditions: THYMIC CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 26, 2026 03:53 UTC
-
New trial aims to stop thymic cancer return after surgery
Disease control Recruiting nowThis study is for people with thymic cancer who have had surgery to remove all visible cancer. It compares two treatments after surgery: radiation alone versus radiation plus chemotherapy. The goal is to see if adding chemotherapy helps keep the cancer from returning. About 172 a…
Matched conditions: THYMIC CARCINOMA
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
Promising drug tested for rare thymus cancers
Disease control Recruiting nowThis study tests a drug called sacituzumab govitecan in adults with advanced thymoma or thymic carcinoma that has worsened after at least one prior treatment. The main goal is to see how many patients' tumors shrink or disappear. Participants receive the drug intravenously weekly…
Matched conditions: THYMIC CARCINOMA
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, and ovarian cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have a specific marke…
Matched conditions: THYMIC CARCINOMA
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New combo therapy shows promise for rare thymic cancer before surgery
Disease control Recruiting nowThis study tests whether combining the drug envolizumab with radiation therapy before surgery can safely shrink tumors in people with locally advanced thymic carcinoma. About 25 adults aged 18-75 who have not had prior treatment will receive the combination, then undergo surgery.…
Matched conditions: THYMIC CARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated May 18, 2026 12:04 UTC